| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The primary molecular targets of 9(Z),11(E)-CLA methyl ester are peroxisome proliferator-activated receptors (PPARs), specifically PPARalpha and PPARgamma, with moderate binding affinity (EC50 in the low micromolar range). It also modulates the activity of NF-kappaB, SREBP-1c, and cyclooxygenase-2 (COX-2). Through these interactions, it influences lipid metabolism, inflammation, and cell proliferation. Additionally, it can incorporate into cellular membranes, altering lipid raft composition and signaling. No single high-affinity receptor has been identified; instead, it acts through multiple pleiotropic mechanisms.
|
|---|---|
| ln Vitro |
In vitro, 9(Z),11(E)-CLA methyl ester inhibits the proliferation of various cancer cell lines including breast (MCF-7, IC50 ~50 uM), colon (HT-29, IC50 ~60 uM), and prostate (PC-3, IC50 ~70 uM). It induces apoptosis via caspase-3 activation and reduces PGE2 production by downregulating COX-2 expression. It also decreases lipid accumulation in adipocytes by activating PPARalpha and reducing SREBP-1c. At 10-50 uM, it suppresses TNF-alpha and IL-6 secretion in LPS-stimulated macrophages. No direct enzyme inhibition is observed; effects are transcriptional.
|
| ln Vivo |
In animal models, 9(Z),11(E)-CLA methyl ester (administered orally or by dietary supplementation at 0.5-1.5% of total fat) reduces body fat mass and improves insulin sensitivity in obese mice. In a rat model of atherosclerosis (0.5% dietary CLA for 12 weeks), it reduces aortic plaque formation by 40% and lowers serum triglycerides. In a mouse mammary tumor model (0.5% CLA in diet), it reduces tumor incidence by 50%. Doses up to 1.5 g/kg body weight in rats show no overt toxicity. However, high doses may cause hepatic steatosis and insulin resistance in some strains. Human trials with CLA mixtures show modest effects; the pure isomer has not been clinically developed.
|
| Enzyme Assay |
Cell‑free receptor binding assays can be performed using human PPARgamma ligand binding domain (LBD) expressed in E. coli. Incubate 50 nM PPARgamma LBD with 10 nM fluorescently labeled PPARgamma probe (e.g., Fluormone-PPARgamma Green) and varying concentrations of 9(Z),11(E)-CLA methyl ester (0.1-100 uM) in assay buffer (50 mM Tris-HCl pH 7.4, 10 mM DTT, 2 mM EDTA, 0.1% BSA) for 2 h at 4degC. Measure fluorescence polarization (ex 485 nm, em 535 nm). For COX-2 inhibition, use a cell‑free COX‑2 assay kit: incubate 10 uL COX-2 enzyme with 1-100 uM test compound and arachidonic acid, measure PGE2 by ELISA. IC50 values are typically >100 uM, indicating weak direct inhibition.
|
| Cell Assay |
Seed HeLa or 3T3-L1 preadipocytes in 96-well plates (10,000 cells/well). After 24 h, treat with 9(Z),11(E)-CLA methyl ester at 1-100 uM (prepared in DMSO, final DMSO <0.1%) in culture medium. For adipocyte differentiation, treat confluent 3T3-L1 with differentiation cocktail (insulin, dexamethasone, IBMX) plus CLA for 7 days. Quantify lipid accumulation by Oil Red O staining (absorbance at 520 nm). For apoptosis, treat MCF-7 cells for 48 h, then stain with annexin V-FITC/PI and analyze by flow cytometry. Measure caspase-3 activity using a fluorogenic substrate (DEVD-AFC). Cytotoxicity (MTT) IC50 is typically around 50-100 uM.
|
| Animal Protocol |
For in vivo efficacy, use female C57BL/6 mice fed a high-fat diet (45% kcal from fat) for 8 weeks to induce obesity. Then administer 9(Z),11(E)-CLA methyl ester by oral gavage at 200 mg/kg/day (in corn oil) for 4 additional weeks. Control receives corn oil only. Measure body weight weekly. At sacrifice, collect epididymal white adipose tissue, liver, and serum. Quantify serum triglycerides, total cholesterol, glucose, and insulin. Perform glucose tolerance test (2 g/kg glucose IP) at week 4. For tumor studies, inject MCF-7 cells subcutaneously into nude mice; when tumors reach 100 mm3, treat with 200 mg/kg CLA methyl ester orally daily for 21 days, measure tumor volume every 3 days.
|
| ADME/Pharmacokinetics |
Pharmacokinetic studies in rats show that after oral administration of 9(Z),11(E)-CLA methyl ester (100 mg/kg), the compound is rapidly absorbed with Cmax ~15 uM at 1-2 h. It is extensively hydrolyzed to the free fatty acid by intestinal and hepatic esterases; the free CLA isomer is the major circulating form. Plasma protein binding >99% (mainly albumin). Half-life of total CLA (free + ester) is approximately 6-8 h. Volume of distribution ~0.3 L/kg. Metabolism involves beta-oxidation and chain shortening. Elimination is primarily via oxidation to CO2 and urinary excretion of metabolites. Oral bioavailability of the methyl ester is ~40% relative to the free acid. No human PK data.
|
| Toxicity/Toxicokinetics |
9(Z),11(E)-CLA methyl ester has low acute toxicity. Oral LD50 in rats >5000 mg/kg. In 90-day feeding studies in rats at dietary levels up to 1.5% (approx. 1 g/kg/day), no significant adverse effects were observed except mild liver enlargement and increased hepatic lipid peroxidation at the highest dose. It is not genotoxic (Ames test negative). In humans, CLA supplements (mixed isomers) at 3-6 g/day are generally well tolerated, with mild gastrointestinal side effects and possible increases in lipid peroxidation markers. High doses may worsen insulin resistance in some individuals. No teratogenicity in rats at 1 g/kg/day. Skin and eye mild irritant.
|
| References | |
| Additional Infomation |
9(Z),11(E)-CLA methyl ester is not an approved drug. It has been investigated in numerous preclinical studies as a potential anti-obesity, anti-cancer, and anti-atherosclerotic agent, but no clinical trials have been conducted with the pure isomer. Most human studies use CLA mixtures (50:50 9Z,11E and 10E,12Z). The compound is commercially available as a research standard. It should be stored at -20degC under argon to prevent oxidation. Molecular formula: C19H34O2, molecular weight: 294.47 g/mol. CAS: 13058-52-1. Not for human consumption.
|
| Molecular Formula |
C19H34O2
|
|---|---|
| Molecular Weight |
294.47
|
| Exact Mass |
294.256
|
| CAS # |
13058-52-1
|
| PubChem CID |
11748436
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
378.5±21.0 °C at 760 mmHg
|
| Flash Point |
100.2±20.4 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.465
|
| LogP |
7.64
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
21
|
| Complexity |
279
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCC/C=C/C=C\\CCCCCCCC(=O)OC
|
| InChi Key |
KVIWYYOMPLJRMC-OCBXPSTGSA-N
|
| InChi Code |
InChI=1S/C19H34O2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19(20)21-2/h8-11H,3-7,12-18H2,1-2H3/b9-8+,11-10-
|
| Chemical Name |
methyl (9Z,11E)-octadeca-9,11-dienoate
|
| Synonyms |
9Z,11E-CLA;Methyl 9(Z),11(E)-octadecadienoate;(9Z,11E)-SFE 19:2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3959 mL | 16.9797 mL | 33.9593 mL | |
| 5 mM | 0.6792 mL | 3.3959 mL | 6.7919 mL | |
| 10 mM | 0.3396 mL | 1.6980 mL | 3.3959 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
